May 1st 2025
Aviva Capital Partners and developer Socius are investing £1 billion to develop a cancer research and treatment center in Sutton, London.
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Implementation of ICH Q3D Elemental Impurities Guideline: Challenges and Opportunities
Assessing risk factors is key to implementing the new ICH Q3D guidelines for elemental impurities.